Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nalpropion Pharmaceuticals Inc.

www.nalpropion.com

Latest From Nalpropion Pharmaceuticals Inc.

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies

Contrave Case Splits US Court In Pyrrhic Victory For Teva

Teva has seen two US patents protecting the Contrave combination of naltrexone and bupropion ruled invalid on appeal. But it is no nearer bringing a generic of the weight-loss drug to market, as the Court of appeals upheld a later-expiring patent, albeit on a split decision.

Intellectual Property Legal Issues
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Nalpropion Pharmaceuticals Inc.
  • Senior Management
  • John Sedor, Chmn. & CEO
    Monica Forbes, VP, CFO
  • Contact Info
  • Nalpropion Pharmaceuticals Inc.
    Phone: (858) 875-8600
    9171 Towne Centre Dr.
    Ste. 270
    San Diego, CA 92122
    USA
UsernamePublicRestriction

Register